Blood Neoplasia
Publisher: Elsevier · ISSN 2950-3280 · 100 articles
- Excess body weight at diagnosis is associated with inferior ALL outcomes in male adolescents in the ALL-BFM 2000 study
- Single-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia
- IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable
- Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis
- Racial and socioeconomic differences in time to treatment initiation and outcomes in aggressive non-Hodgkin lymphoma
- Dose-modified methotrexate, rituximab, and temozolomide induction achieves durable remissions in PCNSL
- Impact of body composition on toxicity and response in patients with advanced-stage Hodgkin lymphoma treated with BV-AVD
- A proliferation score defined by PCLI-anchored transcriptomics predicts outcomes in multiple myeloma
- Refining risk in historically high-risk pediatric B-cell acute lymphoblastic leukemia: response kinetics and outcomes
- Travel time, insurance, and specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia
- A long-term population-based study of lymphoplasmacytic lymphoma and Waldenström macroglobulinemia in Ontario, Canada
- Increased severe neurotoxicity and hospital stay in octogenarians receiving CAR T-cell therapy for large B-cell lymphoma
- Timing of response in patients with relapsed/refractory FLT3mut+ acute myeloid leukemia treated with gilteritinib
- Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML
- CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
- Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia
- A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine
- Prognostic implications of TET2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study
- TCL1A polymorphism predicts AML progression in myeloid neoplasms
- Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes
- Rosai-Dorfman disease: a 30-year institutional study of clinical features, treatment patterns, and outcomes
- Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP– but not Pola-R-CHP–treated patients with DLBCL
- CDK4/6i reverses MEIS2 inhibition of CRL4CRBN and promotes BCMA loss to enhance IMiD/CELMoD therapy in multiple myeloma
- Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia
- CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study
- Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events
- Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia
- Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors
- Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma
- IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience